AZD0530 sensitizes drug‐resistantALK‐positive lung cancer cells by inhibitingSRCsignaling
Open Access
- 10 March 2017
- journal article
- research article
- Published by Wiley in FEBS Open Bio
- Vol. 7 (4) , 472-476
Abstract
Most tumors develop resistance to targeted cancer drugs, even though these drugs have produced substantial clinical responses. Here we established anaplastic lymphoma kinase (ALK)‐positive drug‐resistant lung cancer cell lines, which are resistant to ceritinib (LDK378). We found that ceritinib treatment resulted in robust upregulation ofSRCactivity, as measured by the phosphorylation of theSRCsubstrate paxillin. Knockdown ofSRCalone with siRNAeffectively sensitized ceritinib resistance inALK‐positive cells. Furthermore,SRCinhibition byAZD0530 was effective inALK‐resistant cancer cells. Thus,ALKinhibition by ceritinib may lead to upregulation ofSRCsignaling, andAZD0530 could serve as a potential drug in the clinic to treatALK‐resistant lung cancer patients.Keywords
This publication has 20 references indexed in Scilit:
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 2012
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProceedings of the National Academy of Sciences, 2011
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK InhibitorsNew England Journal of Medicine, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Src signaling in cancer invasionJournal of Cellular Physiology, 2010
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutationsJournal of Clinical Oncology, 2008
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase InhibitorJournal of Medicinal Chemistry, 2006